Amino Acids

drug
On this page

Also known as .alpha.-amino acidsAmino acids 11.4%Amino acids 15%Amino acids 20%Amino acids 4%Amino acids 5%Amino acids 5.4%Amino acids 6%Amino acids 6.5%Amino acids 6.9%Amino acids 8%Amino acids component of procalamineAmino acids nossource unspecifiedL-.alpha.-amino acidsL-amino acidsRenamin w/o electrolytesTrophamine

Summary

Amino Acids (CHEMBL1201498) is an approved unknown (ATC B05BA01); indicated across 9 conditions including kidney failure and muscular atrophy.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • ATC class: B05BA01
  • Indications: 9 conditions
  • Clinical trials: 25

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201498
NameAmino Acids
TypeUnknown
Max phase4
ATCB05BA01

Also known as: .alpha.-amino acids, Amino acids, Amino acids 11.4%, Amino acids 15%, Amino acids 20%, Amino acids 4%, Amino acids 5%, Amino acids 5.4%, Amino acids 6%, Amino acids 6.5%, Amino acids 6.9%, Amino acids 8%

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
kidney failure2MONDO:0001106EFO:1002048
muscular atrophy2MONDO:0004323EFO:0009851
severe acute respiratory syndrome2MONDO:0005091MONDO:0100096
glioma2MONDO:0021042MONDO:0100342
neuroendocrine neoplasm1MONDO:0019496EFO:1001901
injury0MONDO:0021178EFO:0000546

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

PhaseTrials
Not specified20
PHASE23
PHASE31
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03709264PHASE3COMPLETEDIntravenous Amino Acid Therapy for Kidney Protection in Cardiac Surgery.
NCT07001098PHASE2NOT_YET_RECRUITINGAmino Acids for Cardiac Surgery Associated AKI
NCT03013387PHASE2WITHDRAWNDosimetry Guided PRRT With 90Y-DOTATOC
NCT03273712PHASE2COMPLETEDDosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
NCT00872911PHASE1COMPLETEDNutrition and Exercise for Sarcopenia
NCT07422792Not specifiedRECRUITINGAnabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure Patients
NCT00005889Not specifiedUNKNOWNGluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
NCT00557388Not specifiedCOMPLETEDDietary Strategies to Promote Muscle Protein Anabolism in the Elderly
NCT00614133Not specifiedCOMPLETEDEffect of Intravenous Nutrition and Epidural Analgesia on Protein Loss After Surgery
NCT00714675Not specifiedCOMPLETEDCitrulline and Protein Metabolism in the Malnourished Elderly People
NCT01150188Not specifiedCOMPLETEDEffects of Amino Acids on Regional Lipid Metabolism
NCT01208324Not specifiedCOMPLETEDEstrogen and Serotonin on Changing Brain Chemistry
NCT01414946Not specifiedCOMPLETEDThe Effect of Intravenous Nutrition in Patients Undergoing Abdominal Surgery
NCT01495871Not specifiedWITHDRAWNAmino Acid Supplementation in Recovery From Traumatic Brain Injury
NCT01860573Not specifiedCOMPLETEDNeurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants
NCT02370745Not specifiedCOMPLETEDCharacterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle
NCT02487680Not specifiedCOMPLETEDEffects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism on Healthy Subjects
NCT02549443Not specifiedCOMPLETEDThe Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG
NCT02894931Not specifiedUNKNOWNEffects of Dietary Interventions on Serum and Macrophage Atherogenicity
NCT03539809Not specifiedCOMPLETEDBranched Chain Amino Acids Ratio in Medical Foods
NCT03644836Not specifiedCOMPLETEDInterest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease
NCT04064528Not specifiedCOMPLETEDEffects of Age on Amino Acid Delivery to Tendon
NCT04067479Not specifiedCOMPLETEDCan Amino Acid Supplementation Augment the Anabolic Response in Tendon After Exercise
NCT04425642Not specifiedCOMPLETEDEffects of Parenteral Nutrition in HSCT
NCT05971563Not specifiedCOMPLETEDAmino Acid Kinetics of GMP-AA in Healthy Human Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.